Mesalamine in ulcerative colitis (uc) · n=0
Reason given: strategic considerations
Telisotuzumab Vedotin in non-small cell lung cancer · n=0
Reason given: Strategic considerations
Sleep UpPhase 3 · started 2024 · withdrawn Upadacitinib in atopic dermatitis · n=0
Reason given: strategic decision
BOTOX Dose A in ventral hernia · n=0
Reason given: Strategic considerations
Budigalimab in human immuno-deficiency virus (hiv) disease · n=163
Reason given: Company Decision
Darigabat in panic disorder · n=80
Reason given: Sponsor terminated due to significant enrollment and study design challenges
NX-13 250mg in ulcerative colitis · n=81
Reason given: Sponsor Decision\_Not Safety Related
Telisotuzumab Vedotin in non small cell lung cancer · n=9
Reason given: Strategic considerations
Emraclidine 30 mg in schizophrenia · n=698
Reason given: The study was terminated due to business reasons, not safety reasons.
Cariprazine in schizophrenia · n=34
Reason given: Strategic considerations
AIM-CDPhase 2 · started 2022 · terminated ABBV-154 in crohn's disease · n=176
Reason given: Strategic considerations
Cedirogant in psoriasis · n=156
Reason given: Company Decision
BOTOX in episodic migraine · n=775
Reason given: The study was terminated early due to lack of efficacy from the primary analysis results.
ABBV-576 in cystic fibrosis (cf) · n=48
Reason given: Strategic considerations
AIM-PMRPhase 2 · started 2021 · terminated ABBV-154 in polymyalgia rheumatica · n=181
Reason given: Strategic considerations
Cariprazine 0.75 mg/day in generalized anxiety disorder · n=0
Reason given: Strategic Decision
ABBV-154 in rheumatoid arthritis (ra) · n=473
Reason given: Business decision
CVL-871 1.0 mg in apathy in dementia · n=41
Reason given: Sponsor Decision - Not Safety Related
ABBV-4083 in onchocerciasis · n=153
Reason given: Strategic considerations
Upadacitinib in atopic dermatitis (ad) · n=0
Reason given: Strategic considerations
CVL-865 in seizures · n=105
Reason given: Closed early after CVL-865-SZ-001 (NCT04244175) did not meet its primary objective
Paricalcitol in chronic kidney disease (ckd) · n=2
Reason given: Company Decision
AGN-241622 in presbyopia · n=80
Reason given: Strategic considerations
Ravaglimab in sjogren's syndrome (ss) · n=0
Reason given: Study canceled
VIALE-TPhase 3 · started 2020 · terminated Venetoclax in acute myeloid leukemia (aml) · n=465
Reason given: Strategic considerations
Elsubrutinib in rheumatoid arthritis (ra) · n=97
Reason given: Study M16-763 was terminated early as the benefit of each treatment arm from the feeder study (Study M16-063) did not provide appreciable evidence of differentiated clinical effect to warrant further long-term continuation.
venetoclax in multiple myeloma · n=0
Reason given: Strategic considerations
Tilavonemab in alzheimer's disease · n=364
Reason given: Discontinued because of lack of efficacy in the parent study (Study M15-566; NCT02880956).
Venetoclax in multiple myeloma · n=8
Reason given: Following results of the primary progression-free survival analysis from Study NCT02755597, company-sponsored MM studies were placed on partial clinical hold (PCH). Sponsor did not pursue release of the PCH for this study.
Cariprazine in schizophrenia · n=587
Reason given: FDA Released Allergan from this post marketing requirement
Steroid eye drops in glioblastoma multiforme · n=40
Reason given: The study was terminated because clinical development of depatuxizumab mafodotin in glioblastoma was stopped due to lack of survival benefit.
Leucovorin in cancer · n=70
Reason given: Study may continue
Dexamethasone in small cell lung cancer · n=0
Reason given: Strategic considerations
ABBV-8E12 in progressive supranuclear palsy (psp) · n=142
Reason given: This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy.
elagolix in endometriosis · n=11
Reason given: The study was terminated early for business reasons, not for safety concerns.
Dalbavancin in endocarditis · n=2
Reason given: Study stopped due to business reasons.
Ipilimumab in small cell lung cancer · n=42
Reason given: Enrollment was stopped after the dose-limiting toxicity (DLT) evaluation phase of Cohort 2.
MERUPhase 3 · started 2017 · terminated Placebo for dexamethasone in small cell lung cancer · n=748
Reason given: Independent Data Monitoring Committee recommendation
Placebo in progressive supranuclear palsy · n=378
Reason given: This study was prematurely discontinued because the program for progressive supranuclear palsy was discontinued due to lack of efficacy of study drug.
Rovalpituzumab tesirine in malignant melanoma · n=200
Reason given: Strategic considerations
GIFT-RPhase 3 · started 2016 · withdrawn Ombitasvir/paritaprevir/ritonavir in chronic hepatitis c virus · n=0
Reason given: Study halted prematurely, prior to enrollment of first participant
ABT-122 in psoriatic arthritis · n=168
Reason given: Internal business decision
VELIAPhase 3 · started 2015 · terminated Veliparib in ovarian cancer · n=1140
Reason given: Business decision not related to patient safety
ombitasvir/paritaprevir/ritonavir and dasabuvir in chronic hepatitis c infection · n=3
Reason given: Study stopped due to low enrollment
Paclitaxel in non-small cell lung cancer stage iii · n=48
Reason given: Phase 2 was not conducted due to a change in the standard of care for newly diagnosed, unresectable Stage III NSCLC
ABT-SLV176 in hypogonadism · n=0
Reason given: Other - not a safety issue
SONARPhase 3 · started 2013 · terminated Atrasentan in diabetic nephropathy · n=5107
Reason given: Strategic considerations
Placebo in cardiothoracic surgery · n=56
Reason given: Topline results from study M13-796 showed an overall lack of efficacy. There were no safety concerns.
ABT-126 in schizophrenia · n=268
Reason given: Study endpoint in preceding base study M10-855 not met.
ABT-126 in alzheimer's disease · n=343
Reason given: Data obtained from the M11-428 study is not critical to the continued evaluation of ABT-126.
ABT-126 in alzheimer's disease · n=349
Reason given: Data obtained from the M11-427 study is not critical to the continued evaluation of ABT-126.
ABT-652 6 mg in diabetic neuropathic pain · n=1
Reason given: Study Stopped
ABT-436 in major depressive disorder · n=19
Reason given: Decision based on strategic determination; not safety.